Osteoporosis: A Chronic, Manageable Condition — Not a Terminal Disease

Osteoporosis is not a terminal illness. It is a chronic skeletal disorder characterized by low bone mass and microarchitectural deterioration, leading to increased fracture risk. With modern management, individuals live full, active lives.

Fracture Risk and Consequences

• Hip, vertebral, wrist fractures most common.
• Hip fracture: ~20% 1-year mortality (due to comorbidities/complications), 50% lose prior function.
• Vertebral fractures: Often asymptomatic; cause height loss, kyphosis, chronic pain.

Evidence-Based Treatment

Class	Examples	Mechanism	Indication
Bisphosphonates	Alendronate, risedronate, zoledronic acid	Inhibit osteoclast resorption	First-line for most
Denosumab	Prolia (60 mg SC q6mo)	Anti-RANKL	Alternative; renal impairment
Anabolics	Teriparatide, abaloparatide, romosozumab	Stimulate bone formation	High fracture risk; ≤2 yrs
SERM	Raloxifene	Estrogen agonist/antagonist	Postmenopausal women; breast CA risk reduction
Hormone Therapy	Estrogen ± progestin	Preserves BMD	Young postmenopausal women with symptoms

Lifestyle Pillars

• Calcium: 1,000–1,200 mg/day (diet + supplement if needed).
• Vitamin D: 800–2,000 IU/day to maintain 25(OH)D >30 ng/mL.
• Exercise: Weight-bearing + resistance + balance (fall prevention).
• Fall prevention: Home safety, vision check, medication review.
• No smoking; limit alcohol.

Monitoring

• DEXA every 1–2 years on treatment.
• Bone turnover markers (CTX, P1NP) for adherence/response.
• Drug holidays after 3–5 yrs (bisphosphonates) if low risk.

Osteoporosis is treatable. Fractures are preventable. Engage with your healthcare team.